{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T18:27:44Z","timestamp":1783967264611,"version":"3.55.0"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:p>\n                    While mild cognitive impairment (MCI) is a risk factor for dementia, it is currently impossible to predict which patients will go on to develop dementia or Alzheimer\u2019s disease. Given the projected global increase in dementia due to an increasingly aging population, there is an urgent need to develop pharmacological therapies to reduce symptoms of MCI, and to help delay its possible progression to dementia. Choline alphoscerate is a cholinergic precursor naturally found in the brain that has been identified as an essential nutrient and is available as a prescription drug. While the efficacy of choline alphoscerate on cognitive function is well established in patients with MCI, Alzheimer\u2019s disease, and cognitive impairment of vascular origin, emerging evidence suggests that it has neuroprotective effects against\n                    <jats:italic>\u03b2<\/jats:italic>\n                    -amyloid injury and may be useful as a preventive therapy against development of Alzheimer\u2019s disease in patients with MCI. Recent data also show that choline alphoscerate may be effective against non-cognitive symptoms of MCI (e.g., depression, anxiety, irritability, aggression, and apathy). Here we review pharmacological and clinical evidence regarding choline alphoscerate in order to highlight its usefulness in patients with MCI. The potential role of choline alphoscerate in promoting healthy sleep architecture is also explored.\n                  <\/jats:p>","DOI":"10.3389\/fnagi.2025.1613566","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T05:30:39Z","timestamp":1754458239000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Choline alphoscerate: insights between acquired certainties and future perspectives"],"prefix":"10.3389","volume":"17","author":[{"given":"Giovanni","family":"Biggio","sequence":"first","affiliation":[{"name":"Department of Life and Environmental Sciences, University of Cagliari, Cittadella Universitaria di Monserrato","place":["Cagliari, Italy"]},{"name":"Institute of Neuroscience, CNR, Cittadella Universitaria di Monserrato","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Mencacci","sequence":"additional","affiliation":[{"name":"Department of Neuroscience and Mental Health, ASST Fatebenefratelli Sacco","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"ref1","first-page":"268","article-title":"Nootropic therapy of cerebral aging","volume":"8","author":"Abbati","year":"1991","journal-title":"Adv. Ther."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jns.2012.07.003","article-title":"The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results","volume":"322","author":"Amenta","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"S281","DOI":"10.3233\/jad-140150","article-title":"The ASCOMALVA (association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease) trial: interim results after two years of treatment","volume":"42","author":"Amenta","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"ref4","first-page":"54","article-title":"Sintesi dei risultati dello studio \u201cEffetto dell\u2019associazione tra donepezil e il precursore colinergico colina alfoscerato (Delecit\u00ae) sui sintomi della malattia di Alzheimer con danno vascolare associato (ASCOMALVA)\u201d","volume":"6","author":"Amenta","year":"2016","journal-title":"Riv. SMIG"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1016\/s0047-6374(01)00310-4","article-title":"Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches?","volume":"122","author":"Amenta","year":"2001","journal-title":"Mech. Ageing Dev."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1017\/s1092852918001347","article-title":"State of the science on mild cognitive impairment (MCI)","volume":"24","author":"Anderson","year":"2019","journal-title":"CNS Spectr."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3390\/biology10060456","article-title":"Beneficial effects of betaine: a comprehensive review","volume":"10","author":"Arumugam","year":"2021","journal-title":"Biology (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3390\/nu12040910","article-title":"Glutamine supplementation prevents chronic stress-induced mild cognitive impairment","volume":"12","author":"Baek","year":"2020","journal-title":"Nutrients"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/ageing\/afac173","article-title":"Worldwide prevalence of mild cognitive impairment among community dwellers aged 50 years and older: a meta-analysis and systematic review of epidemiology studies","volume":"51","author":"Bai","year":"2022","journal-title":"Age Ageing"},{"key":"ref10","first-page":"1","article-title":"Choline alphoscerate in elderly patients with cognitive decline due to dementing illness","volume":"5","author":"Ban","year":"1991","journal-title":"New Trends Clin. Neuropharmacol."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer's disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1590\/S1980-57642011DN05010008","article-title":"Prevalence of treatable and reversible dementias: a study in a dementia outpatient clinic","volume":"5","author":"Bello","year":"2011","journal-title":"Dement. Neuropsychol."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e892","DOI":"10.1212\/wnl.0000000000207534","article-title":"Incidence and long-term functional outcome of neurologic disorders in hospitalized patients with COVID-19 infected with pre-omicron variants","volume":"101","author":"Beretta","year":"2023","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.2147\/NDT.S223640","article-title":"Subthreshold depression needs a prime time in old age psychiatry? A narrative review of current evidence","volume":"15","author":"Biella","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"108966","DOI":"10.1016\/j.abb.2021.108966","article-title":"An overview of the synaptic vesicle lipid composition","volume":"709","author":"Binotti","year":"2021","journal-title":"Arch. Biochem. Biophys."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3390\/cells13040309","article-title":"Taming microglia in Alzheimer's disease: exploring potential implications of choline alphoscerate via alpha7 nAChR modulation","volume":"13","author":"Cantone","year":"2024","journal-title":"Cells"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3390\/medicina60060925","article-title":"Effect of treatment of the cholinergic precursor choline alphoscerate in mild cognitive dysfunction: a randomized controlled trial","volume":"60","author":"Carotenuto","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3233\/adr-200269","article-title":"Association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in the treatment of depression in patients with Alzheimer's disease","volume":"6","author":"Carotenuto","year":"2022","journal-title":"J. Alzheimers Dis. Rep."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3233\/jad-160675","article-title":"The effect of the association between donepezil and choline alphoscerate on behavioral disturbances in Alzheimer's disease: interim results of the ASCOMALVA trial","volume":"56","author":"Carotenuto","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1002\/cbin.11369","article-title":"Neuroprotective potential of choline alfoscerate against \u03b2-amyloid injury: involvement of neurotrophic signals","volume":"44","author":"Catanesi","year":"2020","journal-title":"Cell Biol. Int."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1177\/15333175221082834","article-title":"Emotion processing dysfunction in Alzheimer's disease: an overview of behavioral findings, systems neural correlates, and underlying neural biology","volume":"37","author":"Chaudhary","year":"2022","journal-title":"Am. J. Alzheimers Dis. Other Dement."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41386-021-01100-8","article-title":"Neuromodulation of prefrontal cortex cognitive function in primates: the powerful roles of monoamines and acetylcholine","volume":"47","author":"Cools","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/s0149-2918(03)90023-3","article-title":"Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial","volume":"25","author":"De Jesus Moreno Moreno","year":"2003","journal-title":"Clin. Ther."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1177\/030006059101900406","article-title":"A multicentre trial to evaluate the efficacy and tolerability of alpha-glycerylphosphorylcholine versus cytosine diphosphocholine in patients with vascular dementia","volume":"19","author":"Di Perri","year":"1991","journal-title":"J. Int. Med. Res."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"10041","DOI":"10.3390\/nu10010041","article-title":"Dietary supplements: regulatory challenges and research resources","volume":"10","author":"Dwyer","year":"2018","journal-title":"Nutrients"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1113\/jp270590","article-title":"Membrane lipid rafts and neurobiology: age-related changes in membrane lipids and loss of neuronal function","volume":"594","author":"Egawa","year":"2016","journal-title":"J. Physiol."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.socscimed.2014.05.007","article-title":"The mix matters: complex personal networks relate to higher cognitive functioning in old age","volume":"125","author":"Ellwardt","year":"2015","journal-title":"Soc. Sci. Med."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s00415-022-11543-8","article-title":"Brain positron emission tomography (PET) and cognitive abnormalities one year after COVID-19","volume":"270","author":"Ferrucci","year":"2023","journal-title":"J. Neurol."},{"key":"ref29","first-page":"159","article-title":"Colina alfoscerato (a-GFC) nel trattamento della demenza multinfartuale. Studio clinico multicentrico comparativo vs CDP-colina","volume":"12","author":"Frattola","year":"1991","journal-title":"Giorn. It. Ric. Clin. Ter."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3390\/nu15132900","article-title":"Choline: an essential nutrient for human health","volume":"15","author":"Gallo","year":"2023","journal-title":"Nutrients"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e1002153","DOI":"10.1371\/journal.pbio.1002153","article-title":"Membrane-derived phospholipids control synaptic neurotransmission and plasticity","volume":"13","author":"Garc\u00eda-Morales","year":"2015","journal-title":"PLoS Biol."},{"key":"ref32","first-page":"331","article-title":"A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline in normal volunteers","volume":"30","author":"Gatti","year":"1992","journal-title":"Int. J. Clin. Pharmacol. Ther. Toxicol."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/s2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019","volume":"7","year":"2022","journal-title":"Lancet Public Health"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"10774","DOI":"10.1021\/acs.jafc.1c03077","article-title":"Understanding choline bioavailability and utilization: first step toward personalizing choline nutrition","volume":"69","author":"Goh","year":"2021","journal-title":"J. Agric. Food Chem."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/geriatrics10020032","article-title":"Choline alphoscerate: a therapeutic option for the management of subthreshold depression in the older population","volume":"10","author":"Granata","year":"2025","journal-title":"Geriatrics (Basel)"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jad.2017.07.022","article-title":"Apathy in early and late-life depression","volume":"223","author":"Groeneweg-Koolhoven","year":"2017","journal-title":"J. Affect. Disord."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"8421","DOI":"10.1177\/2333721418778421","article-title":"Insomnia and mild cognitive impairment","volume":"4","author":"Hamdy","year":"2018","journal-title":"Gerontol. Geriatr. Med."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer's disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jocn.2022.06.006","article-title":"Quantitative electroencephalography changes in patients with mild cognitive impairment after choline alphoscerate administration","volume":"102","author":"Han","year":"2022","journal-title":"J. Clin. Neurosci."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1114s","DOI":"10.1093\/jn\/131.3.1114S","article-title":"Dietary supplements: how they are used and regulated","volume":"131","author":"Hathcock","year":"2001","journal-title":"J. Nutr."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"100","DOI":"10.2174\/187152412800792689","article-title":"An introduction to the nutrition and metabolism of choline","volume":"12","author":"Hollenbeck","year":"2012","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1007\/s11064-022-03622-z","article-title":"Preventive effect of betaine against cognitive impairments in amyloid \u03b2 peptide-injected mice through sirtuin1 in hippocampus","volume":"47","author":"Ibi","year":"2022","journal-title":"Neurochem. Res."},{"key":"ref43","year":"2024"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1186\/s12877-024-05366-7","article-title":"Efficacy and safety of choline alphoscerate for amnestic mild cognitive impairment: a randomized double-blind placebo-controlled trial","volume":"24","author":"Jeon","year":"2024","journal-title":"BMC Geriatr."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1474-4422(19)30368-0","article-title":"The characterisation of subjective cognitive decline","volume":"19","author":"Jessen","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"e661","DOI":"10.1016\/s2468-2667(20)30185-7","article-title":"Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study","volume":"5","author":"Jia","year":"2020","journal-title":"Lancet Public Health"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0074-7742(09)00415-2","article-title":"Reversible dementias","volume":"84","author":"Kabasakalian","year":"2009","journal-title":"Int. Rev. Neurobiol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1148166","DOI":"10.3389\/fendo.2023.1148166","article-title":"Choline supplements: an update","volume":"14","author":"Kansakar","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"100059","DOI":"10.1016\/j.tjpad.2025.100059","article-title":"Association between L-alpha glycerylphosphorylcholine use and delayed dementia conversion: a nationwide longitudinal study in South Korea","volume":"12","author":"Kim","year":"2025","journal-title":"J. Prev Alzheimers Dis."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","article-title":"Alzheimer disease","volume":"7","author":"Knopman","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"10031","DOI":"10.3390\/pharmaceutics15010031","article-title":"Physiologic functions and therapeutic applications of alpha7 nicotinic acetylcholine receptor in brain disorders","volume":"15","author":"Lee","year":"2022","journal-title":"Pharmaceutics"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e38067","DOI":"10.1097\/MD.0000000000038067","article-title":"Comparative study of choline alfoscerate as a combination therapy with donepezil: a mixed double-blind randomized controlled and open-label observation trial","volume":"103","author":"Lee","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11055-010-9377-2","article-title":"Efficacy and safety of choline alphoscerate (Cereton) in patients with Parkinson\u2019s disease with cognitive impairments","volume":"41","author":"Levin","year":"2011","journal-title":"Neurosci. Behav. Physiol."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.yfrne.2014.01.002","article-title":"Sex differences in cognitive impairment and Alzheimer's disease","volume":"35","author":"Li","year":"2014","journal-title":"Front. Neuroendocrinol."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1016\/s0140-6736(17)31363-6","article-title":"Dementia prevention, intervention, and care","volume":"390","author":"Livingston","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nn.3324","article-title":"Prefrontal atrophy, disrupted NREM slow waves and impaired hippocampal-dependent memory in aging","volume":"16","author":"Mander","year":"2013","journal-title":"Nat. Neurosci."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"367","DOI":"10.31887\/DCNS.2006.8.4\/bmcewen","article-title":"Protective and damaging effects of stress mediators: central role of the brain","volume":"8","author":"McEwen","year":"2006","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/npp.2015.171","article-title":"Stress effects on neuronal structure: hippocampus, amygdala, and prefrontal cortex","volume":"41","author":"McEwen","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1600-0447.2008.01326.x","article-title":"Rate of progression of mild cognitive impairment to dementia--meta-analysis of 41 robust inception cohort studies","volume":"119","author":"Mitchell","year":"2009","journal-title":"Acta Psychiatr. Scand."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.3390\/ijms23031217","article-title":"Neurobiological highlights of cognitive impairment in psychiatric disorders","volume":"23","author":"Morozova","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"ref61","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/geriatrics8020038","article-title":"The differential role of executive apathy in Alzheimer's disease dementia, mild cognitive impairment and healthy cognitive ageing","volume":"8","author":"Mougias","year":"2023","journal-title":"Geriatrics (Basel)"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1386224","DOI":"10.3389\/fphar.2024.1386224","article-title":"Pharmacological enhancement of cholinergic neurotransmission alleviates neuroinflammation and improves functional outcomes in a triple transgenic mouse model of Alzheimer's disease","volume":"15","author":"Munafo","year":"2024","journal-title":"Front. Pharmacol."},{"key":"ref63","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0011-393X(05)80518-1","article-title":"A neurotropic approach to the treatment of multi-infarct dementia using L-\u03b1-glycerylphosphorylcholine","volume":"52","author":"Muratorio","year":"1992","journal-title":"Curr. Ther. Res."},{"key":"ref64","year":"2022"},{"key":"ref65","first-page":"29","article-title":"Studio clinico di efficacia e tollerabilita di-GFC (colina-alfoscerato), controllato vs oxiracetam in pazienti affetti da declino cognitivo di grado lieve-moderato su base vascolare","volume":"14","author":"Paciaroni","year":"1993","journal-title":"GIR"},{"key":"ref66","first-page":"61","article-title":"Valutazione di efficacia e tollerabilitadi a-GFC (colina alfoscerato) in pazienti affetti da declino cognitivo di grado lieve-moderato","volume":"4","author":"Palleschi","year":"1992","journal-title":"Geriatria"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00002512-199303020-00006","article-title":"Multicentre study of l-alpha-glyceryl-phosphorylcholine vs ST200 among patients with probable senile dementia of Alzheimer\u2019s type","volume":"3","author":"Parnetti","year":"1993","journal-title":"Drugs Aging"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/s0047-6374(01)00312-8","article-title":"Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data","volume":"122","author":"Parnetti","year":"2001","journal-title":"Mech. Ageing Dev."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jns.2007.01.043","article-title":"Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation?","volume":"257","author":"Parnetti","year":"2007","journal-title":"J. Neurol. Sci."},{"key":"ref70","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/s0166-2236(98)01361-7","article-title":"Acetylcholine in mind: a neurotransmitter correlate of consciousness?","volume":"22","author":"Perry","year":"1999","journal-title":"Trends Neurosci."},{"key":"ref71","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1212\/con.0000000000000313","article-title":"Mild cognitive impairment","volume":"22","author":"Petersen","year":"2016","journal-title":"Continuum (Minneap Minn)"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"92","DOI":"10.17116\/jnevro202412404292","article-title":"Efficacy and safety of choline alfoscerate in the preventive therapy of dementia in elderly patients with mild cognitive impairment: a three-year prospective comparative study","volume":"124","author":"Ponomareva","year":"2024","journal-title":"Zh. Nevrol. Psikhiatr. Im. S S Korsakova"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3233\/jad-141983","article-title":"Apathy treatment in Alzheimer's disease: interim results of the ASCOMALVA trial","volume":"48","author":"Rea","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"ref74","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.yfrne.2013.08.001","article-title":"Estrogen: a master regulator of bioenergetic systems in the brain and body","volume":"35","author":"Rettberg","year":"2014","journal-title":"Front. Neuroendocrinol."},{"key":"ref75","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1038\/s41598-021-83126-y","article-title":"Neuropsychiatric profiles and conversion to dementia in mild cognitive impairment, a latent class analysis","volume":"11","author":"Roberto","year":"2021","journal-title":"Sci. Rep."},{"key":"ref76","doi-asserted-by":"publisher","first-page":"988759","DOI":"10.3389\/fncel.2022.988759","article-title":"Effects of choline containing phospholipids on the neurovascular unit: a review","volume":"16","author":"Roy","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"ref77","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3233\/jad-221189","article-title":"Activity of choline alphoscerate on adult-onset cognitive dysfunctions: a systematic review and meta-analysis","volume":"92","author":"Sagaro","year":"2023","journal-title":"J. Alzheimers Dis."},{"key":"ref78","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/bf03337739","article-title":"Prevalence of aging-associated cognitive decline in an Italian elderly population: results from cross-sectional phase of Italian PRoject on epidemiology of Alzheimer's disease (IPREA)","volume":"22","author":"Scafato","year":"2010","journal-title":"Aging Clin. Exp. Res."},{"key":"ref79","doi-asserted-by":"publisher","first-page":"110817","DOI":"10.1016\/j.exger.2019.110817","article-title":"Aging membranes: unexplored functions for lipids in the lifespan of the central nervous system","volume":"131","author":"Skowronska-Krawczyk","year":"2020","journal-title":"Exp. Gerontol."},{"key":"ref80","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.3390\/nu13062091","article-title":"Alpha-glycerylphosphorylcholine increases motivation in healthy volunteers: a single-blind, randomized, placebo-controlled human study","volume":"13","author":"Tamura","year":"2021","journal-title":"Nutrients"},{"key":"ref81","first-page":"21","article-title":"Studio clinicodell\u2019efficaciaterapeutica e dellatol lerabilit\u00e0dellacolinaalfoscerato in 15 soggetti con compromissionedellefunzioni cognitive successiva ad ischemia cerebralefocaleacuta","volume":"37","author":"Tomasina","year":"1991","journal-title":"Riv. Neuropsichiatr. Sci. Affini."},{"key":"ref82","doi-asserted-by":"publisher","first-page":"e0139065","DOI":"10.1371\/journal.pone.0139065","article-title":"Social participation and the prevention of decline in effectance among community-dwelling elderly: a population-based cohort study","volume":"10","author":"Tomioka","year":"2015","journal-title":"PLoS One"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.2174\/15672050113106660173","article-title":"Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline- containing phospholipid with a still interesting profile as cognition enhancing agent","volume":"10","author":"Traini","year":"2013","journal-title":"Curr. Alzheimer Res."},{"key":"ref84","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3233\/jad-190623","article-title":"Volume analysis of brain cognitive areas in Alzheimer's disease: interim 3-year results from the ASCOMALVA trial","volume":"76","author":"Traini","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"ref85","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1001\/jamapsychiatry.2018.1877","article-title":"Association of apathy with risk of incident dementia: a systematic review and meta-analysis","volume":"75","author":"Van Dalen","year":"","journal-title":"JAMA Psychiatry"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1212\/wnl.0000000000004767","article-title":"Apathy is associated with incident dementia in community-dwelling older people","volume":"90","author":"Van Dalen","year":"","journal-title":"Neurology"},{"key":"ref87","first-page":"141","article-title":"Valutazione clinica e strumentale dell \u2018effetto della colina alfoscerato sul decadimento cerebrale","volume":"5","author":"Vezzetti","year":"1992","journal-title":"Presse Med."},{"key":"ref88","doi-asserted-by":"publisher","first-page":"114474","DOI":"10.1016\/j.biopha.2023.114474","article-title":"Therapeutic potential of natural molecules against Alzheimer's disease via SIRT1 modulation","volume":"161","author":"Zhang","year":"2023","journal-title":"Biomed. Pharmacother."}],"updated-by":[{"DOI":"10.3389\/fnagi.2026.1744201","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000}}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2025.1613566\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:03:24Z","timestamp":1769695404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2025.1613566\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":88,"alternative-id":["10.3389\/fnagi.2025.1613566"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2025.1613566","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"article-number":"1613566"}}